From the Department of Ophthalmology, Beyoglu Eye Training and Research Hospital, University of Health Sciences Turkey, Istanbul, Turkey.
J Cataract Refract Surg. 2021 Feb 1;47(2):221-226. doi: 10.1097/j.jcrs.0000000000000418.
To compare the long-term safety, efficacy, and complications of small-incision lenticule extraction (SMILE) and flexible iris-fixated anterior chamber phakic intraocular lens (pIOL) implantation for the treatment of high myopia.
University of Health Science Turkey, Beyoğlu Eye Training and Research Hospital, İstanbul, Turkey.
Retrospective comparative case series.
Data of patients who underwent SMILE or pIOL (Artiflex) implantation for myopia were retrospectively reviewed. Only patients with preoperative manifest refraction spherical equivalent from -6.00 to -10.00 diopters (D) were included in the study.
There were 47 eyes of 32 patients in the SMILE group and 52 eyes of 29 patients in the pIOL group. The mean postoperative follow-up was 63.75 ± 18.40 months in the SMILE group and 65.38 ± 16.22 months in the p-IOL group (P = .71). At 6 years postoperatively, refractive predictability was slightly better in the pIOL group, and the percentages of eyes within ±0.50 D of the attempted correction were 77% and 83% in the SMILE and pIOL groups, respectively. Although mean uncorrected distance visual acuity was comparable (SMILE, 0.12 ± 0.06 logarithm of the minimum angle of resolution [logMAR]; p-IOL, 0.09 ± 0.05 logMAR), the safety indices (1.08 ± 0.22 vs 1.11 ± 0.20; P = .02) and the efficacy indices (0.92 ± 0.24 vs 1.11 ± 0.22; P = .03) were statistically significantly higher after pIOL implantation. Despite a mean of 11.09% of the endothelial cell being lost at 6 years after pIOL implantation, no pIOL was explanted due to endothelial cell loss.
In this comparative and long-term study, iris-fixated anterior chamber pIOL implantation for high myopic correction showed slightly better safety and efficacy profiles but with statistically significant endothelial cell loss.
比较小切口微透镜提取术(SMILE)和可调节虹膜固定前房有晶状体眼人工晶状体(pIOL)植入治疗高度近视的长期安全性、有效性和并发症。
土耳其健康科学大学,贝尤鲁眼科培训和研究医院,伊斯坦布尔,土耳其。
回顾性对比病例系列。
回顾性分析接受 SMILE 或 pIOL(Artiflex)植入术治疗近视的患者数据。仅纳入术前等效球镜屈光度为-6.00 至-10.00 屈光度(D)的患者。
SMILE 组 32 例 47 眼,pIOL 组 29 例 52 眼。SMILE 组的平均术后随访时间为 63.75±18.40 个月,pIOL 组为 65.38±16.22 个月(P=0.71)。术后 6 年,pIOL 组的屈光预测性稍好,SMILE 组和 pIOL 组分别有 77%和 83%的眼屈光度在±0.50 D 的目标矫正范围内。虽然未矫正远视力相当(SMILE 组为 0.12±0.06 最小角分辨对数视力[logMAR];pIOL 组为 0.09±0.05 logMAR),但安全性指数(1.08±0.22 比 1.11±0.20;P=0.02)和有效性指数(0.92±0.24 比 1.11±0.22;P=0.03)在 pIOL 植入后统计学上更高。尽管植入 pIOL 6 年后平均有 11.09%的内皮细胞丢失,但由于内皮细胞丢失,没有 pIOL 被取出。
在这项比较和长期研究中,虹膜固定前房 pIOL 植入术矫正高度近视显示出稍好的安全性和有效性,但内皮细胞丢失有统计学意义。